Research on Toxoplasmosis reveals potential vaccine strategy targeting essential splicing protein, offering protection ...

On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson's disease in Q4 2025 Strengthened balance sheet with recent financing Advancing innovative POZ Platform ...

Ann Telnaes won for “delivering piercing commentary on powerful people and institutions with deftness, creativity – and a ...

Investors in these stocks should be very aware that early-stage biotech stocks have huge upside but also bust potential, and to invest within your risk tolerance accordingly. Billy Duberstein and ...

The CRISPR biotech is now shelving the autoimmune program and slashing staff in order to focus its resources and its finances on the two lead cancer programs, whose data readouts have been delayed ...

1.1a Congress must establish a National Biotechnology Coordination Office (NBCO) within the Executive Office of the President with a director, appointed by the President, who would coordinate ...

The recently announced expansion will add to the roughly 400 jobs already promised in central Ohio by the biotech company and bring its total local investment to $1.4 billion. The expansion is on ...

Animation, Cartoon Network Studios, Hanna-Barbera Studios Europe, said in a statement. “I want to thank Marcel Jean and the festival leadership for entrusting us with this year’s trailer ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

Young is one of more than 1,000 dog owners participating in a first-of-its-kind clinical trial at more than 70 facilities around the country and spearheaded by Bay Area biotech company Loyal.

Warner Bros. Animation, along with its sister studios, Cartoon Network Studios and Hanna-Barbera Studios Europe, has announced its programming line-up for the upcoming Annecy animation festival in ...

Market turmoil may have frozen the traditional IPO pipeline, but German antibody biotech Veraxa is turning to the special purpose acquisition company (SPAC) model to hop onto the Nasdaq.